Frontiers in Immunology (Jan 2024)

J-shaped association of dietary catechins intake with the prevalence of osteoarthritis and moderating effect of physical activity: an American population-based cohort study

  • Yuesong Fu,
  • Lu Li,
  • Jing Gao,
  • Fazheng Wang,
  • Zihan Zhou,
  • Yiwei Zhang

DOI
https://doi.org/10.3389/fimmu.2023.1287856
Journal volume & issue
Vol. 14

Abstract

Read online

BackgroundCatechins are a class of natural compounds with a variety of health benefits, The relationship between catechins and the prevalence of osteoarthritis (OA) is unknown. This study investigated the associations between daily intake of catechins and the prevalence of OA among American adults and assessed the moderating effect of physical activity (PA).MethodsThis study included 10,039 participants from the National Health and Nutrition Examination Survey (2007–2010,2017-2018). The logistic regression, weighted quantile sum (WQS) regression, and restricted cubic spline (RCS) regression models were conducted to explore the associations between daily intake of catechins and the prevalence of OA. Moreover, interaction tests were performed to assess the moderating effect of PA.ResultsAfter multivariable adjustment, the weighted multivariable logistic regression and RCS regression analyses revealed significant J-shaped non-linear correlations between intakes of epigallocatechin and epigallocatechin 3-gallate had significant associations with the prevalence of OA among in U.S. adults. WQS regression analysis showed that excessive epigallocatechin intake was the most significant risk factor for OA among all subtypes of catechins. In the interaction assay, PA showed a significant moderating effect in the relationship between epigallocatechin intake and OA prevalence.ConclusionsThe intake of gallocatechin and gallocatechin 3-gallate had a significant negative correlation with the prevalence of OA and the dose-response relationship was J-shaped.PA below 150 MET-min/week and the threshold intakes of 32.70mg/d for epigallocatechin and 76.24mg/d for epigallocatechin 3-gallate might be the targets for interventions to reduce the risk of developing OA.

Keywords